Detalles de la búsqueda
1.
Secukinumab demonstrates high and sustained efficacy in nail psoriasis: post hoc analysis from phase III trials in patients with psoriatic arthritis.
Br J Dermatol
; 187(3): 438-441, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35257363
2.
Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data.
Acta Derm Venereol
; 102: adv00698, 2022 Apr 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-35146532
3.
Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy.
J Hepatol
; 62(1): 41-7, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25152207
4.
Safety of Secukinumab from 1 Million Patient-Years of Exposure: Experience from Post-Marketing Setting and Clinical Trials.
Dermatol Ther (Heidelb)
; 14(3): 729-743, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38451423
5.
Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study.
RMD Open
; 9(2)2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-37094983
6.
Impact of hyperuricaemia on patients with psoriatic arthritis treated with secukinumab in the FUTURE 2-5 and MAXIMISE studies.
RMD Open
; 9(4)2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37945285
7.
Effects of secukinumab on synovitis and enthesitis in patients with psoriatic arthritis: 52-week clinical and ultrasound results from the randomised, double-blind ULTIMATE trial with open label extension.
Semin Arthritis Rheum
; 63: 152259, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37660536
8.
Efficacy of Secukinumab Across Subgroups and Overall Safety in Pediatric Patients with Moderate to Severe Plaque Psoriasis: Week 52 Results from a Phase III Randomized Study.
Paediatr Drugs
; 24(4): 377-387, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35698000
9.
Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients.
Hepatology
; 52(5): 1611-20, 2010 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-20931556
10.
Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B.
Liver Int
; 31(5): 676-84, 2011 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-21457439
11.
A Pooled Analysis Reporting the Efficacy and Safety of Secukinumab in Male and Female Patients with Ankylosing Spondylitis.
Rheumatol Ther
; 8(4): 1775-1787, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34618347
12.
Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis.
JAMA Dermatol
; 157(1): 43-51, 2021 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33001147
13.
Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
Antimicrob Agents Chemother
; 54(3): 1242-7, 2010 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-20028815
14.
NT-proBNP Response to Sacubitril/Valsartan in Hospitalized Heart Failure Patients With Reduced Ejection Fraction: TRANSITION Study.
JACC Heart Fail
; 8(10): 822-833, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32800508
15.
Initiation of sacubitril/valsartan shortly after hospitalisation for acutely decompensated heart failure in patients with newly diagnosed (de novo) heart failure: a subgroup analysis of the TRANSITION study.
Eur J Heart Fail
; 22(2): 303-312, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31820537
16.
Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B.
J Hepatol
; 51(1): 11-20, 2009 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-19345439
17.
Secukinumab demonstrates superior efficacy and a faster response in clearing skin in Asian subjects with moderate to severe plaque psoriasis compared with ustekinumab: Subgroup analysis from the CLEAR study.
J Dermatol
; 46(9): 752-758, 2019 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-31342560
18.
Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study.
Eur J Heart Fail
; 21(8): 998-1007, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31134724
19.
Safety and tolerability of indacaterol in asthma: a randomized, placebo-controlled 28-day study.
Respir Med
; 101(10): 2065-75, 2007 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-17643277
20.
Long-Term Telbivudine Treatment Results in Resolution of Liver Inflammation and Fibrosis in Patients with Chronic Hepatitis B.
Adv Ther
; 32(8): 727-41, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-26329749